Agomab Therapeutics (AGMB) Retained Earnings (2024 - 2025)
Agomab Therapeutics (AGMB) posted quarterly Retained Earnings of -$1.1 million for Q4 2025, down 9.04% year-over-year from -$1.2 million in Q4 2024, and down 9.04% quarter-over-quarter from -$1.0 million in Q4 2024.
Agomab Therapeutics (AGMB) Retained Earnings (2024 - 2025) Analysis & Trends
Agomab Therapeutics' Retained Earnings history runs 2 years deep, the most recent figure standing at -$1.1 million for Q4 2025.
- In Q4 2025, Retained Earnings fell 9.04% year-over-year to -$1.1 million; the TTM figure through Dec 2025 stood at -$1.1 million (down 9.04% YoY), while the FY2025 annual figure was -$1.1 million, down 7.66% from the prior year.
- Retained Earnings for Q4 2025 stood at -$1.1 million, down from -$1.0 million in the prior quarter.
- The five-year high for Retained Earnings was -$1.0 million in Q4 2024, with the low at -$1.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 4.38 Bn |
| 10 | Agomab Therapeutics | 7.26 Mn | -250.32 Mn | - | -247.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.13 Mn |
| Dec 31, 2024 | -1.03 Mn |